



News Updates: April 9, 2014

Patents/Compulsory Licensing/Intellectual Property

Website: Pharmabiz

Edition: Online

Date: April 9, 2014

Headline: [Patent Controller issues draft 'Guidelines for Examination of Patent Applications in the field of Pharmaceuticals'](#)

Synopsis: India's Controller General of Patents, Designs and Trade Marks has issued draft 'Guidelines for Examination of Patent Applications in the field of Pharmaceuticals' which will help the Examiners and the Controllers of the Patent Office in achieving consistently uniform standards of patent examination and grant of patents. These guidelines are supplemental to the practices and procedures followed by the Patent Office as published in the 'Manual of Patent Office Practice and Procedure', "Guidelines For Examination of Biotechnology Applications" and the "Guidelines For Processing of Patent Applications Relating to Traditional Knowledge and Biological Material".

Manifesto- Health services

Publication: The Economic Times

Edition: Online

Date: April 8, 2014

Headline: [Kiran Mazumdar Shaw on 5 reasons why BJP's manifesto stands apart](#)

Synopsis: The BJP's manifesto highlights the need for a universal healthcare program which hinges on affordability and access. The document talks about leveraging telemedicine and mobile healthcare for rural healthcare delivery, addressing the shortfall of healthcare professionals in the country, modernizing government hospitals and upgrading healthcare infrastructure among the various measures needed to achieve the goal of 'healthcare for all.'

Publication: Business Standard

Edition: National

Date: April 9, 2014

Opinion piece: Arvind Panagariya, professor at Columbia University

Headline: [The choice on offer](#)

Synopsis: Both the Congress and the Bharatiya Janata Party (BJP) manifestos are now out. They, along with the speeches by the leaders of the two parties, provide the basis for the comparison of likely administrations under them. There is agreement between the two sides on objectives: both would like to rapidly end poverty, illiteracy and ill health and modernise India. But the preferred policy instruments markedly differ.

Sun Pharma- Ranbaxy deal

Publication: Mint

Edition: National

Date: April 9, 2014

Headline: [Dilip Shanghvi's big challenge: Integrating Ranbaxy with Sun Pharma](#)

Synopsis: Sun Pharmaceutical Industries Ltd is all set to become the world's fifth largest generics drugs maker, following its decision to buy Ranbaxy Laboratories Ltd from Japan's Daiichi Sankyo Co. Ltd in an all-stock deal worth \$3.2 billion (around Rs.19,200 crore). This is Sun Pharma's 17th such

deal. Though the company's founder and managing director Dilip Shanghvi is looking forward to realizing synergies through the deal, managing Ranbaxy will certainly be a big challenge.

Similar reports in-

The Economic Times- [Sun Pharma-Ranbaxy deal: We'll Guide Ranbaxy, says Dilip Shanghvi](#)

The Economic Times- [Ranbaxy Laboratories' TL Easwar of API quits post 'introspection'](#)

Business Standard- [Sun Pharma-Ranbaxy deal may come under Sebi lens](#)

The Times of India- [Sun Pharma-Ranbaxy deal: Why it's a good deal for Shanghvi](#)

The Financial Chronicle- [Sun Pharma to face challenges in rectifying quality control](#)

The Hindu- [Was there insider trading in Ranbaxy stock?](#)

The New Indian Express- [Sky is the Limit for Indian Drug Firms](#)

Drug pricing/ Access

Publication: The Hindu Business Line

Edition: National

Date: April 9, 2014

Headline: [NPPA caps prices of 17 formulation-based drugs](#)

Synopsis: The National Pharmaceuticals Pricing Authority (NPPA) last week fixed an upper cap on 17 formulation-based bulk drugs. The drugs listed in the order included Ciprofloxacin hydrochloride, Sulfasalazine, Promethazine, Prednisolone, Metronidazole, Promethazine and Carbamazepine.

Publication: Business Standard

Edition: Online

Date: April 8, 2014

Headline: [Gilead aims to license hepatitis C drug to 3-4 Indian firms](#)

Synopsis: Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations. Clifford Samuel, head of access operations and emerging markets at the U.S. drugmaker, told Reuters he expected to have deals in place shortly with the Indian firms, which would be able to produce the drug in high volumes and at low margins.

General Industry

Publication: The Economic Times

Edition: National

Date: April 9, 2014

Headline: [Japan drugmaker Takeda says will fight \\$6.0 billion US damages order](#)

Synopsis: Takeda Pharmaceutical Co Ltd said it would contest \$6 billion in punitive damages imposed by a US federal jury in a case alleging Japan's largest drugmaker had concealed cancer risks associated with its Actos diabetes drug. Eli Lilly and Co, Takeda's co-defendant in the case, was ordered to pay \$3 billion in punitive damages.

Similar reports in-

Mint- [Takeda, Lilly jury awards \\$9 billion over hiding Actos risks](#)

Business Standard- [US jury orders Takeda, Eli Lilly to pay \\$9-bn damages](#)

The Financial Express- [US jury hits Takeda, Eli Lilly with \\$9 bn penalty](#)

Reuters- [Japan drugmaker Takeda to fight \\$6 billion damages awarded by U.S. jury](#)